Works by Velde, Helgi

Results: 68
    1
    2
    3
    4

    Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
    By:
    • Delforge, Michel;
    • Terpos, Evangelos;
    • Richardson, Paul G.;
    • Shpilberg, Ofer;
    • Khuageva, Nuriet K.;
    • Schlag, Rudolf;
    • Dimopoulos, Meletios A.;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Petrucci, Maria T.;
    • Samoilova, Olga S.;
    • Mateos, Maria-Victoria;
    • Magen-Nativ, Hila;
    • Goldschmidt, Hartmut;
    • Esseltine, Dixie-Lee;
    • Ricci, Deborah S.;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • van de Velde, Helgi
    Publication type:
    Article
    5

    Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
    By:
    • Dimopoulos, Meletios A.;
    • Mateos, Maria-Victoria;
    • Richardson, Paul G.;
    • Schlag, Rudolf;
    • Khuageva, Nuriet K.;
    • Shpilberg, Ofer;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Palumbo, Antonio;
    • Wu, Ka Lung;
    • Esseltine, Dixie-Lee;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • Van De Velde, Helgi;
    • San Miguel, Jesús F.
    Publication type:
    Article
    6
    7

    The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.

    Published in:
    American Journal of Hematology, 2015, v. 90, n. 5, p. E86, doi. 10.1002/ajh.23967
    By:
    • Harrison, Simon J.;
    • Quach, Hang;
    • Link, Emma;
    • Feng, Huaibao;
    • Dean, Joanne;
    • Copeman, Michael;
    • Van De Velde, Helgi;
    • Schwarer, Anthony;
    • Baker, Bartrum;
    • Spencer, Andrew;
    • Catalano, John;
    • Campbell, Philip;
    • Augustson, Bradley;
    • Romeril, Ken;
    • Prince, Henry Miles
    Publication type:
    Article
    8
    9

    A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

    Published in:
    American Journal of Hematology, 2015, v. 90, n. 1, p. 42, doi. 10.1002/ajh.23868
    By:
    • Orlowski, Robert Z.;
    • Gercheva, Liana;
    • Williams, Cathy;
    • Sutherland, Heather;
    • Robak, Tadeusz;
    • Masszi, Tamás;
    • Goranova-Marinova, Vesselina;
    • Dimopoulos, Meletios A.;
    • Cavenagh, James D.;
    • Špička, Ivan;
    • Maiolino, Angelo;
    • Suvorov, Alexander;
    • Bladé, Joan;
    • Samoylova, Olga;
    • Puchalski, Thomas A.;
    • Reddy, Manjula;
    • Bandekar, Rajesh;
    • van de Velde, Helgi;
    • Xie, Hong;
    • Rossi, Jean-Franςois
    Publication type:
    Article
    10

    The Cost-Effectiveness of Initial Treatment of Multiple Myelomain the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide...

    Published in:
    Oncologist, 2013, v. 18, n. 1, p. 27, doi. 10.1634/theoncologist.2011-0380
    By:
    • Garrison, Louis P.;
    • Wang, Si‐Tien;
    • Huang, Hui;
    • Ba‐Mancini, Abbie;
    • Shi, Hongliang;
    • Chen, Kristina;
    • Korves, Caroline;
    • Dhawan, Ravinder;
    • Cakana, Andrew;
    • Velde, Helgi;
    • Corzo, Deyanira;
    • Duh, Mei Sheng
    Publication type:
    Article
    11

    Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01149-w
    By:
    • Richardson, Paul G.;
    • Perrot, Aurore;
    • Mikhael, Joseph;
    • Martin, Thomas;
    • Beksac, Meral;
    • Spicka, Ivan;
    • Capra, Marcelo;
    • D'Agostino, Mattia;
    • Sonneveld, Pieter;
    • Bisht, Kamlesh;
    • Fukao, Taro;
    • Zhang, Rick;
    • Tada, Keisuke;
    • Tekle, Christina;
    • Macé, Sandrine;
    • Klippel, Zandra;
    • van de Velde, Helgi;
    • Moreau, Philippe
    Publication type:
    Article
    12
    13
    14
    15
    16

    Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 1, p. 35, doi. 10.1007/s00280-013-2314-7
    By:
    • Thomas, Sheeba;
    • Suvorov, Alexander;
    • Noens, Lucien;
    • Rukavitsin, Oleg;
    • Fay, Joseph;
    • Wu, Ka;
    • Zimmerman, Todd;
    • Velde, Helgi;
    • Bandekar, Rajesh;
    • Puchalski, Thomas;
    • Qi, Ming;
    • Uhlar, Clarissa;
    • Samoylova, Olga
    Publication type:
    Article
    17
    18
    19

    Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice.

    Published in:
    Health Science Reports, 2019, v. 2, n. 1, p. N.PAG, doi. 10.1002/hsr2.104
    By:
    • Hulin, Cyrille;
    • Rubia, Javier;
    • Dimopoulos, Meletios A.;
    • Terpos, Evangelos;
    • Katodritou, Eirini;
    • Hungria, Vania;
    • De Samblanx, Hadewijch;
    • Stoppa, Anne‐Marie;
    • Aagesen, Jesper;
    • Sargin, Deniz;
    • Sioni, Anastasia;
    • Belch, Andrew;
    • Diels, Joris;
    • Olie, Robert A.;
    • Robinson, Don;
    • Potamianou, Anna;
    • Velde, Helgi;
    • Delforge, Michel
    Publication type:
    Article
    20

    Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>*</sup>.

    Published in:
    Leukemia & Lymphoma, 2019, v. 60, n. 1, p. 172, doi. 10.1080/10428194.2017.1321750
    By:
    • Robak, Tadeusz;
    • Huang, Huiqiang;
    • Jin, Jie;
    • Zhu, Jun;
    • Liu, Ting;
    • Samoilova, Olga;
    • Pylypenko, Halyna;
    • Verhoef, Gregor;
    • Siritanaratkul, Noppadol;
    • Osmanov, Evgenii;
    • Pereira, Juliana;
    • Mayer, Jiri;
    • Hong, Xiaonan;
    • Okamoto, Rumiko;
    • Pei, Lixia;
    • Rooney, Brendan;
    • van de Velde, Helgi;
    • Cavalli, Franco
    Publication type:
    Article
    21

    Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 4, p. 896, doi. 10.1080/10428194.2017.1365855
    By:
    • Drach, Johannes;
    • Bunworasate, Udomsak;
    • Masliak, Zvenyslava;
    • Vilchevskaya, Kateryna;
    • Robak, Tadeusz;
    • Pei, Lixia;
    • Rooney, Brendan;
    • van de Velde, Helgi;
    • Cavalli, Franco;
    • Huang, Huiqiang;
    • Samoilova, Olga;
    • Belch, Andrew;
    • Farber, Charles;
    • Bosly, André;
    • Novak, Jan;
    • Zaucha, Jan;
    • Dascalescu, Angela
    Publication type:
    Article
    22

    Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.

    Published in:
    Leukemia & Lymphoma, 2017, v. 58, n. 8, p. 1968, doi. 10.1080/10428194.2016.1272688
    By:
    • Skarbnik, Alan P.;
    • Ma, Esprit;
    • Lafeuille, Marie-Hélène;
    • Fortier, Jonathan;
    • Feldman, Tatyana;
    • Duh, Mei Sheng;
    • van de Velde, Helgi;
    • Niculescu, Liviu;
    • Bonthapally, Vijayveer;
    • Goy, André
    Publication type:
    Article
    23
    24
    25

    Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres.

    Published in:
    British Journal of Haematology, 2014, v. 165, n. 1, p. 39, doi. 10.1111/bjh.12717
    By:
    • Robinson, Don;
    • Reynolds, Matthew;
    • Casper, Corey;
    • Dispenzieri, Angela;
    • Vermeulen, Jessica;
    • Payne, Krista;
    • Schramm, Judy;
    • Ristow, Kay;
    • Desrosiers, Marie‐Pierre;
    • Yeomans, Karen;
    • Teltsch, Dana;
    • Swain, Richard;
    • Habermann, Thomas M.;
    • Rotella, Philip;
    • Van de Velde, Helgi
    Publication type:
    Article
    26

    A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

    Published in:
    British Journal of Haematology, 2013, v. 161, n. 3, p. 357, doi. 10.1111/bjh.12266
    By:
    • Voorhees, Peter M.;
    • Manges, Robert F.;
    • Sonneveld, Pieter;
    • Jagannath, Sundar;
    • Somlo, George;
    • Krishnan, Amrita;
    • Lentzsch, Suzanne;
    • Frank, Richard C.;
    • Zweegman, Sonja;
    • Wijermans, Pierre W.;
    • Orlowski, Robert Z.;
    • Kranenburg, Britte;
    • Hall, Brett;
    • Casneuf, Tineke;
    • Qin, Xiang;
    • Velde, Helgi;
    • Xie, Hong;
    • Thomas, Sheeba K.
    Publication type:
    Article
    27

    Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial

    Published in:
    British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x
    By:
    • Richardson, Paul;
    • Schlag, Rudolf;
    • Khuageva, Nuriet;
    • Dimopoulos, Meletios;
    • Shpilberg, Ofer;
    • Kropff, Martin;
    • Vekemans, Marie-Christiane;
    • Petrucci, Maria Teresa;
    • Rossiev, Viktor;
    • Hou, Jian;
    • Robak, Tadeusz;
    • Mateos, Maria-Victoria;
    • Anderson, Kenneth;
    • Esseltine, Dixie-Lee;
    • Cakana, Andrew;
    • Liu, Kevin;
    • Deraedt, William;
    • van de Velde, Helgi;
    • San Miguel, Jesús F.
    Publication type:
    Article
    28
    29
    30
    31

    Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.

    Published in:
    Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0
    By:
    • Moreau, Philippe;
    • Karamanesht, Ievgenii I.;
    • Donmikova, Natalia;
    • Kyselyova, Maryna Y.;
    • Vilchevska, Kateryna V.;
    • Doronin, Vadim A.;
    • Schmidt, Alexander;
    • Hulin, Cyrille;
    • Leleu, Xavier;
    • Esseltine, Dixie-Lee;
    • Venkatakrishnan, Karthik;
    • Skee, Donna;
    • Huaibao Feng;
    • Girgis, Suzette;
    • Cakana, Andrew;
    • van de Velde, Helgi;
    • Deraedt, William;
    • Facon, Thierry
    Publication type:
    Article
    32
    33

    Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.

    Published in:
    2016
    By:
    • Mateos, Maria-Victoria;
    • Oriol, Albert;
    • Martínez-López, Joaquín;
    • Teruel, Ana-Isabel;
    • Bengoechea, Enrique;
    • Palomera, Luis;
    • de Arriba, Felipe;
    • Esseltine, Dixie-Lee;
    • Cakana, Andrew;
    • Pei, Lixia;
    • van de Velde, Helgi;
    • Miguel, Jesus;
    • Martínez-López, Joaquín;
    • Miguel, Jesus San
    Publication type:
    journal article
    34

    Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 4, p. 619, doi. 10.1007/s10637-017-0531-3
    By:
    • Bahleda, Rastislav;
    • Le Deley, Marie-Cécile;
    • Bernard, Apexa;
    • Chaturvedi, Shalini;
    • Hanley, Michael;
    • Poterie, Audrey;
    • Gazzah, Anas;
    • Varga, Andreea;
    • Touat, Mehdi;
    • Deutsch, Eric;
    • Massard, Christophe;
    • Van De Velde, Helgi;
    • Hollebecque, Antoine;
    • Sallansonnet-Froment, Magali;
    • Ricard, Damien;
    • Taillia, Hervé;
    • Angevin, Eric;
    • Ribrag, Vincent;
    • Soria, Jean-Charles
    Publication type:
    Article
    35
    36

    Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
    By:
    • Lesokhin, Alexander;
    • LeBlanc, Richard;
    • Dimopoulos, Meletios A.;
    • Capra, Marcelo;
    • Carlo‐Stella, Carmelo;
    • Karlin, Lionel;
    • Castilloux, Jean‐Francois;
    • Forsberg, Peter;
    • Parmar, Gurdeep;
    • Tosikyan, Axel;
    • Pour, Ludek;
    • Ribrag, Vincent;
    • Ribolla, Rossella;
    • Abdallah, Al‐Ola;
    • Le Roux, Nadia;
    • Dong, Liyan;
    • van de Velde, Helgi;
    • Mayrargue, Laurent;
    • Lépine, Lucie;
    • Macé, Sandrine
    Publication type:
    Article
    37
    38
    39

    A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies.

    Published in:
    British Journal of Haematology, 2024, v. 205, n. 6, p. 2262, doi. 10.1111/bjh.19784
    By:
    • Zabaleta, Aintzane;
    • Blanco, Laura;
    • Kim, Peter S.;
    • Bisht, Kamlesh;
    • Wang, Hongfang;
    • Van de Velde, Helgi;
    • Lasa, Marta;
    • Tamariz‐Amador, Luis‐Esteban;
    • Rodriguez‐Otero, Paula;
    • San‐Miguel, Jesús;
    • Paiva, Bruno;
    • Martín‐Sánchez, Esperanza
    Publication type:
    Article
    40

    A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies.

    Published in:
    British Journal of Haematology, 2024, v. 205, n. 6, p. 2262, doi. 10.1111/bjh.19784
    By:
    • Zabaleta, Aintzane;
    • Blanco, Laura;
    • Kim, Peter S.;
    • Bisht, Kamlesh;
    • Wang, Hongfang;
    • Van de Velde, Helgi;
    • Lasa, Marta;
    • Tamariz‐Amador, Luis‐Esteban;
    • Rodriguez‐Otero, Paula;
    • San‐Miguel, Jesús;
    • Paiva, Bruno;
    • Martín‐Sánchez, Esperanza
    Publication type:
    Article
    41

    Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics.

    Published in:
    British Journal of Haematology, 2021, v. 194, n. 1, p. 120, doi. 10.1111/bjh.17499
    By:
    • Harrison, Simon J.;
    • Perrot, Aurore;
    • Alegre, Adrian;
    • Simpson, David;
    • Wang, Ming Chung;
    • Spencer, Andrew;
    • Delimpasi, Sosana;
    • Hulin, Cyrille;
    • Sunami, Kazutaka;
    • Facon, Thierry;
    • Vlummens, Philip;
    • Yong, Kwee;
    • Campana, Frank;
    • Inchauspé, Marlène;
    • Macé, Sandrine;
    • Risse, Marie‐Laure;
    • Velde, Helgi;
    • Richardson, Paul
    Publication type:
    Article
    42

    A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

    Published in:
    British Journal of Haematology, 2017, v. 178, n. 4, p. 547, doi. 10.1111/bjh.14708
    By:
    • Laubach, Jacob P.;
    • Moslehi, Javid J.;
    • Francis, Sanjeev A.;
    • San Miguel, Jesús F.;
    • Sonneveld, Pieter;
    • Orlowski, Robert Z.;
    • Moreau, Philippe;
    • Rosiñol, Laura;
    • Faber, Edward A.;
    • Voorhees, Peter;
    • Mateos, Maria ‐ Victoria;
    • Marquez, Loreta;
    • Feng, Huaibao;
    • Desai, Avinash;
    • Velde, Helgi;
    • Elliott, Jennifer;
    • Shi, Hongliang;
    • Dow, Edward;
    • Jobanputra, Nishith;
    • Esseltine, Dixie ‐ Lee
    Publication type:
    Article
    43
    44

    Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

    Published in:
    British Journal of Haematology, 2015, v. 171, n. 3, p. 344, doi. 10.1111/bjh.13582
    By:
    • Ludwig, Heinz;
    • Greil, Richard;
    • Masszi, Tamas;
    • Spicka, Ivan;
    • Shpilberg, Ofer;
    • Hajek, Roman;
    • Dmoszynska, Anna;
    • Paiva, Bruno;
    • Vidriales, María‐Belén;
    • Esteves, Graca;
    • Stoppa, Anne Marie;
    • Robinson, Don;
    • Chaturvedi, Shalini;
    • Ataman, Ozlem;
    • Enny, Christopher;
    • Feng, Huaibao;
    • Velde, Helgi;
    • Viterbo, Luisa
    Publication type:
    Article
    45
    46

    Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.

    Published in:
    Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 2, p. 376, doi. 10.1002/cpt.1047
    By:
    • Gupta, Neeraj;
    • Hanley, Michael J.;
    • Diderichsen, Paul M.;
    • Yang, Huyuan;
    • Ke, Alice;
    • Teng, Zhaoyang;
    • Labotka, Richard;
    • Berg, Deborah;
    • Patel, Chirag;
    • Liu, Guohui;
    • Velde, Helgi;
    • Venkatakrishnan, Karthik
    Publication type:
    Article
    47

    Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.

    Published in:
    CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 6, p. 766, doi. 10.1002/psp4.12789
    By:
    • Rachedi, Fatiha;
    • Koiwai, Kimiko;
    • Gaudel‐Dedieu, Nadia;
    • Sebastien, Bernard;
    • Thai, Hoai‐Thu;
    • Brillac, Claire;
    • Fau, Jean Baptiste;
    • Nguyen, Laurent;
    • van de Velde, Helgi;
    • Veyrat‐Follet, Christine;
    • Semiond, Dorothée
    Publication type:
    Article
    48
    49

    Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 424, doi. 10.1016/j.clml.2022.03.009
    By:
    • Moreau, Philippe;
    • Parmar, Gurdeep;
    • Prince, Miles;
    • Ocio, Enrique M.;
    • Karanes, Chatchada;
    • Madan, Sumit;
    • Oriol, Albert;
    • Bories, Pierre;
    • Delforgel, Michel;
    • Gabrail, Nashat;
    • Semiondi, Dorothee;
    • Jia, Nan;
    • Macé, Sandrine;
    • Suzan, Florence;
    • van de Velde, Helgi;
    • Quach, Hang
    Publication type:
    Article
    50

    P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S159, doi. 10.1016/S2152-2650(21)02344-2
    By:
    • Špicka, Ivan;
    • Moreau, Philippe;
    • Martin, Thomas;
    • Facon, Thierry;
    • Martinez, Gracia;
    • Oriol, A.;
    • Youngil Koh;
    • Lim, Andrew;
    • Mikala, Gábor;
    • Rosiñol, Laura;
    • Münci Yagci;
    • Cavo, Michele;
    • Risse, Marie-Laure;
    • Asset, Gaëlle;
    • Macé, Sandrine;
    • van de Velde, Helgi;
    • Kwee Yong
    Publication type:
    Article